Literature DB >> 17903694

Renal function dependent association of AGTR1 polymorphism (A1166C) and electrocardiographic left-ventricular hypertrophy.

Tom D J Smilde1, Mike W Zuurman, Hans L Hillege, Dirk J van Veldhuisen, Wiek H van Gilst, Gerrit van der Steege, Adriaan A Voors, Jan A Kors, Paul E de Jong, Gerjan Navis.   

Abstract

BACKGROUND: The association of renin-angiotensin system (RAS) polymorphisms and left-ventricular hypertrophy (LVH) may depend on the presence of risk factors for LVH, such as renal dysfunction. We studied whether renal function modulates the association between RAS polymorphisms and LVH in a cross-sectional study of 8592 inhabitants of Groningen.
METHODS: Left-ventricular hypertrophy was determined with electrocardiograms, using the Cornell voltage-duration product. The following RAS polymorphisms were determined: angiotensin II type-1 receptor (AGTR1 A1166C), angiotensin-converting enzyme (ACE) insertion/deletion (I/D), and angiotensinogen (AGT G-6A). The AGTR1 A1166C and ACE I/D polymorphisms were in Hardy-Weinberg equilibrium.
RESULTS: Electrocardiographic LVH was present in 417 (5.0%) subjects. Subjects with LVH were older (53 v 49 years) and overall had more cardiovascular risk factors. Using logistic regression, creatinine clearance interacted with the relationship between the AGTR1 A1166C polymorphism and LVH (beta, -0.19; P = .033). In subjects with the CC genotype, in contrast to carriers of an A allele, the prevalence of LVH increased with more pronounced renal dysfunction. Creatinine clearance also interacted with the relationship between the ACE I/D polymorphism and LVH (beta, 0.12; P = .037), although less strongly, and the other way around. Creatinine clearance did not influence the association between the AGT G-6A polymorphism and LVH (beta, -0.006; P = .491).
CONCLUSIONS: In this population-based study, the AGTR1 A1166C polymorphism was associated with LVH, dependent on concomitant renal dysfunction. A weaker renal function dependent association between the ACE I/D polymorphism and LVH was also observed. Renal function should be taken into account as a relevant environmental factor for the pathogenetic effects of RAS polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17903694     DOI: 10.1016/j.amjhyper.2007.04.023

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  7 in total

1.  Evaluation of hypertrophic cardiomyopathy: new horizons for CMR?

Authors:  E E van der Wall; H M Siebelink; J J Bax
Journal:  Neth Heart J       Date:  2010-03       Impact factor: 2.380

Review 2.  Unravelling the Lesser Known Facets of Angiotensin II Type 1 Receptor.

Authors:  Mayank Chaudhary; Shashi Chaudhary
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

3.  Left ventricular mass assessment by CMR; how to define the optimal index.

Authors:  E E van der Wall; H M Siebelink; J J Bax
Journal:  Int J Cardiovasc Imaging       Date:  2010-03-06       Impact factor: 2.357

4.  Common genetic variation, residential proximity to traffic exposure, and left ventricular mass: the multi-ethnic study of atherosclerosis.

Authors:  Victor C Van Hee; Sara D Adar; Adam A Szpiro; R Graham Barr; Ana Diez Roux; David A Bluemke; Lianne Sheppard; Edward A Gill; Hossein Bahrami; Christina Wassel; Michele M Sale; David S Siscovick; Jerome I Rotter; Stephen S Rich; Joel D Kaufman
Journal:  Environ Health Perspect       Date:  2010-03-22       Impact factor: 9.031

5.  Cardiovascular Disease, Single Nucleotide Polymorphisms; and the Renin Angiotensin System: Is There a MicroRNA Connection?

Authors:  Terry S Elton; Sarah E Sansom; Mickey M Martin
Journal:  Int J Hypertens       Date:  2010-08-04       Impact factor: 2.420

Review 6.  Developments in renal pharmacogenomics and applications in chronic kidney disease.

Authors:  Ariadna Padullés; Inés Rama; Inés Llaudó; Núria Lloberas
Journal:  Pharmgenomics Pers Med       Date:  2014-08-28

7.  Identification of potential candidate genes for hypertensive nephropathy based on gene expression profile.

Authors:  Zhi Chen; Hao Wu; Guohua Wang; Ye Feng
Journal:  BMC Nephrol       Date:  2016-10-18       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.